Olumacostat glasaretil Acetyl-CoA carboxylase (ACC) inhibitor Acne therapy

被引：1

作者：

Baroudi, B. ^{[1
]}

Shealy, E. R. ^{[1
]}

Cardwell, C. A. ^{[1
]}

Alinia, H. ^{[1
]}

Feldman, S. R. ^{[1
,2
,3
]}

机构：

[1] Wake Forest Sch Med, Ctr Dermatol Res, Dept Dermatol, Winston Salem, NC 27157 USA

[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27157 USA

[3] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27157 USA

来源：

DRUGS OF THE FUTURE | 2018年 / 43卷 / 03期

关键词：

Olumacostat glasaretil; Acne; Papules; Pustules; Topical; Androgenic; Acetyl-CoA carboxylase (ACC) inhibitor; BENZOYL PEROXIDE; VULGARIS; MANAGEMENT; RESISTANCE; COENZYME;

D O I：

10.1358/dof.2018.043.03.2766398

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Acne vulgaris is a common dermatologic condition affecting adolescents and adults. Systemic and topical therapies have been developed to target different mechanisms in the pathogenesis of acne. Olumacostat glasaretil (OG) is a novel topical agent that targets sebum production in the treatment of acne vulgaris. OG's active metabolite acts as a competitive inhibitor of the rate-limiting enzyme of fatty acid synthesis, acetylcoenzyme A (CoA) carboxylase (ACC). ACC catalyzes malonylCoA formation and sebum production. OG is efficacious in the treatment of acne vulgaris and has a low side effect profile. Phase IIa and IIb trials note side effects including applicationsite erythema and dryness, and nasopharyngitis. Phase III trials are currently underway. The new mechanism of action of OG is sensible, attractive and exciting, but the available data do not demonstrate that it provides a quantum leap forward over existing therapies.

引用

页码：175 / 179

页数：5

共 50 条

[31] Design and Synthesis of a Dual-Ligand Inhibitor for Acetyl-CoA Carboxylase
Silvers, Molly A.
Taylor, Carol M.
Waldrop, Grover L.
FASEB JOURNAL, 2013, 27
[32] Design and synthesis of a dual-ligand inhibitor for acetyl-CoA carboxylase
Silvers, Molly A.
Taylor, Carol M.
Waldrop, Grover L.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
[33] Activity and structure of human acetyl-CoA carboxylase targeted by a specific inhibitor
Jang, SoRi
Gornicki, Piotr
Marjanovic, Jasmina
Bass, Ethan
Iurcotta, Toni P.
Rodriguez, Pedro
Austin, Jotham, II
Haselkorn, Robert
FEBS LETTERS, 2018, 592 (12): : 2048 - 2058
[34] QUANTITATION OF ACETYL-COA CARBOXYLASE (ACC) BY ELECTROBLOT TRANSFER AND AVIDIN-PEROXIDASE DETECTION
MAPES, JP
FEDERATION PROCEEDINGS, 1983, 42 (07) : 1854 - 1854
[35] Recent Advances in the Development of Acetyl-CoA Carboxylase (ACC) Inhibitors for the Treatment of Metabolic Disease
Bourbeau, Matthew P.
Bartberger, Michael D.
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (02) : 525 - 536
[36] Effect of Acetyl-CoA Carboxylase (ACC) on Lipid Production in Endophytic Fungi fromTorreya grandis
Yang, Y.
Jin, Q.
Chen, J.
Wu, Zh.
Jin, Zh.
MICROBIOLOGY, 2020, 89 (04) : 443 - 450
[37] The Pharmacokinetics of GS-0976, an Acetyl-CoA Carboxylase (ACC) Inhibitor, in Subjects with Mild, Moderate, and Severe Hepatic Impairment
Nelson, Cara
Weber, Elijah
Yue, Mun Sang
Millward, Victoria
Qin, Ann R.
Marbury, Thomas C.
Lawitz, Eric J.
Li, Georgia
Myers, Robert P.
Kirby, Brian
HEPATOLOGY, 2018, 68 : 979A - 980A
[38] Acetyl-CoA Carboxylase (ACC) Inhibitor, CP640186, Effectively Inhibited Dengue Virus (DENV) Infection via Regulating ACC Phosphorylation
Wu, Wenyu
Chen, Ruilin
Wan, Yuanda
Li, Liren
Han, Jiajia
Lei, Qiyun
Chen, Zhipeng
Liu, Shuwen
Yao, Xingang
MOLECULES, 2022, 27 (23):
[39] HEPATIC ZONATION OF ACETYL-COA CARBOXYLASE ACTIVITY
EVANS, JL
QUISTORFF, B
WITTERS, LA
BIOCHEMICAL JOURNAL, 1990, 270 (03) : 665 - 672
[40] Recent Advances in Acetyl-CoA Carboxylase Inhibitors
Bourbeau, Matthew P.
Allen, John G.
Gu, Wei
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 45, 2010, 45 : 95 - 108

← 1 2 3 4 5 →